Carilex Medical, Inc (7726) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Carilex Medical, Inc TWD 27.66, price TWD 32.10, upside -13.8%, quality 40 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Carilex Medical, Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Sep 24, 2026.
How to read this chart
10‑month range 30.70 TWD – 41.90 TWD · fair‑value band 22.47 TWD – 34.86 TWD · the 32.10 TWD price screens above the 27.66 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Sep 24, 2026.
Follow Carilex Medical in your weekly email
Every Wednesday you see whether Carilex Medical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Carilex Medical, Inc. engages in the research and development, manufacture, and sale of medical devices for wound care management worldwide. It offers support surfaces, chair cushions, and negative pressure wound therapy products to prevent and manage pressure sores and wounds. The company was founded in 1985 and is headquartered in Taoyuan City, Taiwan.
Stock analysis
Carilex Medical, Inc (7726) currently trades at 32.10 TWD, while our model-based Fair Value estimate is 27.66 TWD, implying the stock looks roughly 16.0% overvalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of 34.27 TWD per share, and 6 of the 7 models we run sit above the 32.10 TWD price.
Bear case: the Asset-Based group reads lowest at 9.60 TWD, and 1 of the 7 models stay below the price. Evidence for this calculation is low.
Scenario range: 22.47 TWD (bear) to 34.86 TWD (bull), the price of 32.10 TWD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
Carilex Medical, Inc reported revenue of 339M TWD in FY2025 versus 388M TWD in FY2021, a compound −3.3%/yr. Reported net income was −29.0M TWD in FY2025.
Key figures
Market cap 652M TWD (≈ $20.5M) · EPS (TTM) −1.43 TWD · Net margin −8.6% · Return on assets (EBIT) 3.9% · Free cash flow 36.0M TWD · Net cash 65.2M TWD.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (medium confidence).
What moves the price
For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at −14%, 7726 screens richer than that median.
Fair Value models
Bear 22.47 TWDFair Value 27.66 TWDBull 34.86 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.27/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
−3.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.5%
Start year 2020 (pandemic)
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
21.0% (2020) → −12.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+8.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about +7.2% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 365 stocks
Beats the industry median on 3/9 measures
Overall it trails its industry peers.
Valuation
Quality Score40 · Below median
Fair Value upside−14% · Above median
Profitability
Return on assets0% · Below median
Net margin (TTM)−9% · Below median
Operating margin (TTM)0% · Below median
Growth and dividend
Revenue growth0% · Below median
Dividend yield (TTM)0.0% · Bottom 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Carilex Medical, Inc (7726) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 27.66 TWD versus a price of 32.10 TWD, about −14% upside (overvalued).
What is the fair value of 7726?
Our model-based fair value for Carilex Medical, Inc is 27.66 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 32.10 TWD.
What is the quality score of 7726?
Carilex Medical, Inc has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Carilex Medical, Inc (7726)?
Our model-based price target is the fair value of 27.66 TWD (as of Sep 24, 2026) from 7 valuation models. Cautious scenario 22.47 TWD, optimistic scenario 34.86 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Carilex Medical, Inc stock forecast for 2026?
Our models put fair value at 27.66 TWD, about −14% upside versus a price of 32.10 TWD (overvalued). Cautious scenario 22.47 TWD, optimistic scenario 34.86 TWD. The calculation is refreshed regularly with new filings.
What growth is priced into Carilex Medical, Inc (7726)?
For today's price to be fair in a discounted-cash-flow model, Carilex Medical, Inc would have to grow free cash flow by +8.9 % per year for five years (discount rate 10.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -0.5 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 7726 use?
Our models discount Carilex Medical, Inc at 10.3 %: a base by market capitalisation (nano), country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Carilex Medical, Inc that is +8.9 % per year a year over ten years, using the same discount rate (10.3 %) and the same formula as our fair value.
How much growth has Carilex Medical, Inc (7726) delivered so far?
Over the past 5 years revenue at Carilex Medical, Inc grew -0.5 % a year. The price currently implies +8.9 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Carilex Medical, Inc (7726) growing?
The median revenue growth in the sector is +0.0 % a year. That is the yardstick for the growth priced into Carilex Medical, Inc (+8.9 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Carilex Medical, Inc (7726)?
The free-cash-flow yield on the price is 5.53 %: that much free cash flow Carilex Medical, Inc produces per unit of market value. When it exceeds the discount rate of our models (10.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Carilex Medical, Inc (7726)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Carilex Medical, Inc it is 27.66 TWD per share (as of Sep 24, 2026), against a price of 32.10 TWD. It is the blended result of 7 valuation models (cash flow, earnings, asset, dividend).
Is Carilex Medical, Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 7726 trades above its calculated fair value: price 32.10 TWD, fair value 27.66 TWD, a gap of about −14% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 7726?
No. The price is what the market pays today (32.10 TWD); the fair value is what the company's own numbers justify (27.66 TWD). For Carilex Medical, Inc the two are 4.44 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Carilex Medical, Inc worth?
The market values Carilex Medical, Inc at about 652M TWD (market capitalisation, as of Sep 24, 2026). Per share that is 32.10 TWD; our models calculate a fair value of 27.66 TWD per share.
What do the bullish and bearish scenarios say about 7726?
Our models span a range for Carilex Medical, Inc: cautious scenario 22.47 TWD, base 27.66 TWD, optimistic 34.86 TWD per share (as of Sep 24, 2026, price 32.10 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
Which stocks are comparable to Carilex Medical, Inc?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Carilex Medical, Inc stock attractive at the current price?
The data as of Sep 24, 2026: price 32.10 TWD, calculated fair value 27.66 TWD (−14%), Quality Score 40/100, from 7 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 7726 calculated?
We run Carilex Medical, Inc through 7 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 27.66 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Carilex Medical, Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Carilex Medical, Inc (7726)?
The closing price on Sep 24, 2026 was 32.10 TWD. Our model-based fair value is 27.66 TWD, about −14% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Carilex Medical, Inc right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of Carilex Medical, Inc
How large is the market capitalisation of Carilex Medical, Inc (7726)?
The market capitalisation of Carilex Medical, Inc is 652M TWD (≈ $20.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Carilex Medical, Inc (7726)?
Earnings per share at Carilex Medical, Inc are −1.43 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Carilex Medical, Inc (7726)?
The net margin of Carilex Medical, Inc is −8.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of Carilex Medical, Inc (7726)?
On an EBIT basis the return on assets of Carilex Medical, Inc is 3.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much net cash does Carilex Medical, Inc (7726) hold?
Carilex Medical, Inc holds more cash than debt, 65.2M TWD net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Carilex Medical, Inc in the live analysis
One click puts Carilex Medical, Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
